SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:umu-50382"
 

Sökning: onr:"swepub:oai:DiVA.org:umu-50382" > Effect of valsartan...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005075naa a2200913 4500
001oai:DiVA.org:umu-50382
003SwePub
008111207s2010 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-503822 URI
0247 a https://doi.org/10.1056/NEJMoa10011212 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a McMurray, John J4 aut
2451 0a Effect of valsartan on the incidence of diabetes and cardiovascular events
264 1c 2010
338 a print2 rdacarrier
520 a BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
7001 a Holman, Rury R4 aut
7001 a Haffner, Steven M4 aut
7001 a Bethel, M Angelyn4 aut
7001 a Holzhauer, Björn4 aut
7001 a Hua, Tsushung A4 aut
7001 a Belenkov, Yuri4 aut
7001 a Boolell, Mitradev4 aut
7001 a Buse, John B4 aut
7001 a Buckley, Brendan M4 aut
7001 a Chacra, Antonio R4 aut
7001 a Chiang, Fu-Tien4 aut
7001 a Charbonnel, Bernard4 aut
7001 a Chow, Chun-Chung4 aut
7001 a Davies, Melanie J4 aut
7001 a Deedwania, Prakash4 aut
7001 a Diem, Peter4 aut
7001 a Einhorn, Daniel4 aut
7001 a Fonseca, Vivian4 aut
7001 a Fulcher, Gregory R4 aut
7001 a Gaciong, Zbigniew4 aut
7001 a Gaztambide, Sonia4 aut
7001 a Giles, Thomas4 aut
7001 a Horton, Edward4 aut
7001 a Ilkova, Hasan4 aut
7001 a Jenssen, Trond4 aut
7001 a Kahn, Steven E4 aut
7001 a Krum, Henry4 aut
7001 a Laakso, Markku4 aut
7001 a Leiter, Lawrence A4 aut
7001 a Levitt, Naomi S4 aut
7001 a Mareev, Viacheslav4 aut
7001 a Martinez, Felipe4 aut
7001 a Masson, Chantal4 aut
7001 a Mazzone, Theodore4 aut
7001 a Meaney, Eduardo4 aut
7001 a Nesto, Richard4 aut
7001 a Pan, Changyu4 aut
7001 a Prager, Rudolf4 aut
7001 a Raptis, Sotirios A4 aut
7001 a Rutten, Guy E H M4 aut
7001 a Sandström, Herbertu Umeå universitet,Allmänmedicin4 aut0 (Swepub:umu)hesa0015
7001 a Schaper, Frank4 aut
7001 a Scheen, Andre4 aut
7001 a Schmitz, Ole4 aut
7001 a Sinay, Isaac4 aut
7001 a Soska, Vladimir4 aut
7001 a Stender, Steen4 aut
7001 a Tamás, Gyula4 aut
7001 a Tognoni, Gianni4 aut
7001 a Tuomilehto, Jaako4 aut
7001 a Villamil, Alberto S4 aut
7001 a Vozár, Juraj4 aut
7001 a Califf, Robert M4 aut
7102 a Umeå universitetb Allmänmedicin4 org
7730 t New England Journal of Medicineg 362:16, s. 1477-1490q 362:16<1477-1490x 0028-4793x 1533-4406
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-50382
8564 8u https://doi.org/10.1056/NEJMoa1001121

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy